[T.S.R:16913] Cadila HC-BUY

Ø  Cadila Healthcare Limited is a pharmaceutical company, which is involved in the business of manufacturing and marketing of pharmaceutical products.

Ø  CHL is the 5th largest pharmaceutical company in the domestic market with a sales force of 4,400, well-positioned to address the opportunity in the domestic market.

Ø  Cadila is well geographically diversified having a presence in Brazil and South Africa , France , Spain and Japan . The other markets with reasonable presence include Sri Lanka , Myanmar , Uganda and Sudan , wherein in CDH ranks among the top three Indian pharmaceutical companies.

Ø  Cadila have 617 molecules and combinations in the market place, it covers 67.8% of the domestic formulation market in value terms and has a 3.9% market share.

Ø  Cadila currently has a pipeline of 57 ANDAs awaiting approval in US. The company expects to launch eight to ten products every year in the US .

Ø  Consistent top-line growth above 20% over the past four years. Robust revenue growth (up 18% YoY) and strong operating performance (up 22% YoY) resulted in 28% YoY growth in APAT. 

Ø  Management has re-iterated its revenue guidance of US$1bn for FY11E and domestic growth to sustain at 15% level. Management's stated aspiration to reach US$3bn in revenue by FY15. Supplies to Abbott, scaling up of JV's provide long term visibility.

Ø  The stock has seen bottom formation around 730 levels with good volumes. In terms of Risk-Reward calculation this stock looks very attractive. One can initiate long position with stop loss of 730 levels and for the target of 850 levels in coming days.
 

Safe Harbor Statement:

Some forward looking statements on projections, estimates, expectations & outlook are included to enable a better comprehension of the Company prospects. Actual results may, however, differ materially from those stated on account of factors such as changes in government regulations, tax regimes, economic developments within India and the countries within which the Company conducts its business, exchange rate and interest rate movements, impact of competing products and their pricing, product demand and supply constraints.

 

Nothing in this article is, or should be construed as, investment advice.

 

 

 

 

 

--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."